125 related articles for article (PubMed ID: 20432663)
21. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
Donovan MJ; Cordon-Cardo C
Mol Diagn Ther; 2017 Apr; 21(2):115-123. PubMed ID: 28000172
[TBL] [Abstract][Full Text] [Related]
22. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
[TBL] [Abstract][Full Text] [Related]
23. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].
Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I
Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600
[TBL] [Abstract][Full Text] [Related]
24. [Molecular pathology of colorectal cancer].
Bosman FT; Joris F
Rev Med Suisse Romande; 1999 Oct; 119(10):775-82. PubMed ID: 10582488
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
[TBL] [Abstract][Full Text] [Related]
26. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.
Nguyen JK; Magi-Galluzzi C
Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322
[TBL] [Abstract][Full Text] [Related]
27. The current status and problems confronted in delivering precision medicine in Japan and Europe.
Bando H
Curr Probl Cancer; 2017; 41(3):166-175. PubMed ID: 28391973
[TBL] [Abstract][Full Text] [Related]
28. Morphological clues to the appropriate recognition of hereditary renal neoplasms.
Moch H; Ohashi R; Gandhi JS; Amin MB
Semin Diagn Pathol; 2018 May; 35(3):184-192. PubMed ID: 29454577
[TBL] [Abstract][Full Text] [Related]
29. Individualized threshold for tumor segmentation in 18F-FDG PET/CT imaging: The key for response evaluation of neoadjuvant chemoradiation therapy in patients with rectal cancer?
Fagundes TC; Mafra A; Silva RG; Castro ACG; Silva LC; Aguiar PT; Silva JA; P Junior E; Machado AM; Mamede M
Rev Assoc Med Bras (1992); 2018 Feb; 64(2):119-126. PubMed ID: 29641665
[TBL] [Abstract][Full Text] [Related]
30. [Pathological evaluation after preoperative neoadjuvant treatment in rectal cancer].
Niu D; Xue W
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Jun; 21(6):632-636. PubMed ID: 29968237
[TBL] [Abstract][Full Text] [Related]
31. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
32. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
33. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of magnetic resonance imaging in rectal cancer depends on location of the tumor.
Peschaud F; Cuenod CA; Benoist S; Julié C; Beauchet A; Siauve N; Taieb-Kasbi F; Penna C; Nordlinger B
Dis Colon Rectum; 2005 Aug; 48(8):1603-9. PubMed ID: 15937629
[TBL] [Abstract][Full Text] [Related]
35. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
36. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.
de Rosa N; Rodriguez-Bigas MA; Chang GJ; Veerapong J; Borras E; Krishnan S; Bednarski B; Messick CA; Skibber JM; Feig BW; Lynch PM; Vilar E; You YN
J Clin Oncol; 2016 Sep; 34(25):3039-46. PubMed ID: 27432916
[TBL] [Abstract][Full Text] [Related]
37. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
Sinicrope FA; Okamoto K; Kasi PM; Kawakami H
Clin Gastroenterol Hepatol; 2016 May; 14(5):651-8. PubMed ID: 26872400
[TBL] [Abstract][Full Text] [Related]
38. Prediction of Biologic Aggressiveness in Colorectal Cancer by p53/K-ras-2 Topographic Genotyping.
Finkelstein SD; Przygodzki R; Pricolo VE; Sakallah SA; Swalsky PA; Bakker A; Lanning R; Bland KI; Cooper DL
Mol Diagn; 1996 Jun; 1(1):5-28. PubMed ID: 10330194
[TBL] [Abstract][Full Text] [Related]
39. Cystic fibrosis in the era of precision medicine.
Paranjape SM; Mogayzel PJ
Paediatr Respir Rev; 2018 Jan; 25():64-72. PubMed ID: 28372929
[TBL] [Abstract][Full Text] [Related]
40. [Personalized medicine--the future is already here].
Abadi-Korek I; Shemer J
Harefuah; 2011 May; 150(5):451-2, 490. PubMed ID: 21678641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
